Cellectar Biosciences, Inc. (CLRB) Free cash flow 2016–2025
Cellectar Biosciences, Inc. (CLRB) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$23.1MFY2025 · since FY2016: -$8.4M → -$23.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$23.1M | +51.5% |
| FY2024 | -$47.7M | -43.5% |
| FY2023 | -$33.2M | -30.6% |
| FY2022 | -$25.4M | -12.1% |
| FY2021 | -$22.7M | -62.3% |
| FY2020 | -$14.0M | -19.4% |
| FY2019 | -$11.7M | +0.9% |
| FY2018 | -$11.8M | -4.0% |
| FY2017 | -$11.4M | -36.1% |
| FY2016 | -$8.4M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More CLRB financial trends
CLRB RevenueCLRB Net incomeCLRB Net marginCLRB Gross profitCLRB Gross marginCLRB Operating incomeCLRB Operating marginCLRB Operating cash flowCLRB Capital expendituresCLRB Return on equityCLRB Stock buybacksCLRB Dividends paidCLRB Total assetsCLRB Total liabilitiesCLRB Shareholders’ equityCLRB overview →